Praxis Precision Medicines Inc. (PRAX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Praxis Precision Medicines, Inc. (PRAX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Praxis Precision Medicines, Inc. ( PRAX ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division All right. We're going to get started with our next session.
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy?
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains?
Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program October 16, 2025 8:00 AM EDT Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Ritu Baral - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Joon Lee - Truist Securities, Inc., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Douglas Tsao - H.C.
Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants a - Corporate Participant Marcio Silva De'Souza - President, CEO & Director Steven Petrou - Co-Founder & Chief Scientific Officer Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division Brian Peter Skorney - Robert W. Baird & Co. Incorporated, Research Division Yatin Suneja - Unidentified Company Guggenheim Securities - Unidentified Company David Timothy Hoang - Deutsche Bank AG, Research Division Daniel Ferry - Lifesci Advisors, LLC Douglas Dylan Tsao - H.C.
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market.
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.94 per share versus the Zacks Consensus Estimate of a loss of $2.96. This compares to loss of $2.97 per share a year ago.
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO Tim Kelly - CFO Conference Call Participants Ritu Baral - TD Cowen Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Douglas Tsao - H.C. Wainwright Kambiz Yazdi - Jefferies Ami Fadia - Needham Joel Beatty - Baird Laura Chico - Wedbush Securities Operator Good day and thank you for standing by.
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago.
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
